Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $21,150.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 846 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $21,150.00. Following the completion of the transaction, the chief financial officer directly owned 146,600 shares in the company, valued at $3,665,000. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, September 2nd, Scott Blumberg sold 652 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total transaction of $16,300.00.
• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Price Performance

NASDAQ:CBLL traded up $0.50 during trading hours on Thursday, reaching $25.00. The stock had a trading volume of 734,947 shares, compared to its average volume of 280,012. The stock has a market capitalization of $959.50 million, a PE ratio of -14.20 and a beta of 0.95. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.63. The company has a 50 day moving average price of $21.51 and a two-hundred day moving average price of $19.79. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. As a group, sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. raised its stake in shares of CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Strs Ohio purchased a new stake in CeriBell in the first quarter valued at approximately $27,000. Larson Financial Group LLC increased its holdings in CeriBell by 1,403.1% in the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after buying an additional 2,680 shares during the period. Caitong International Asset Management Co. Ltd raised its position in CeriBell by 8,735.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company’s stock worth $60,000 after buying an additional 2,708 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in CeriBell during the 2nd quarter valued at approximately $53,000.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CBLL shares. BTIG Research restated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Friday, September 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial reissued a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a research note on Thursday, September 3rd. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.40.

CeriBell Company Profile

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.